Investigating a natural compound for treating triple-negative breast cancer
Mechanistic Evaluation of Macrocyclic Diterpenoids with Selective Triple Negative Breast Cancer Activity
This study is looking at a natural compound called yuanhuacine to see if it can help treat triple-negative breast cancer by targeting specific cancer cells, with the hope of finding better treatments for patients facing this tough type of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of the Incarnate Word NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10932738 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a challenging type of cancer that lacks targeted therapies. The study aims to explore a natural compound called yuanhuacine, which has shown potential in selectively targeting specific subtypes of TNBC. Researchers will investigate how this compound works at the molecular level, particularly its effects on a protein known as PKC βII, which may influence the cancer cells' response to treatment. By understanding these mechanisms, the goal is to develop more effective therapies for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple-negative breast cancer, particularly those with the basal-like 2 subtype.
Not a fit: Patients with other types of breast cancer or those who do not have triple-negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted treatment options for patients with triple-negative breast cancer.
How similar studies have performed: While the approach of using natural compounds for cancer treatment is not entirely novel, the specific focus on yuanhuacine and its selective action on TNBC subtypes represents a potentially innovative direction in cancer therapy.
Where this research is happening
San Antonio, United States
- University of the Incarnate Word — San Antonio, United States (Active)
Researchers
- Principal investigator: Fermaintt, Charles Steven — University of the Incarnate Word
- Study coordinator: Fermaintt, Charles Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.